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Abstract 
Background: There is a paucity of recent epidemiological data on bone cancers. 
The aim of this study was to describe incidence and survival patterns for bone 
cancers diagnosed during 1981 – 2002.  
Methods: Cases aged 0 – 39 years (236 osteosarcomas, 166 Ewing sarcomas 
and 73 chondrosarcomas) were analysed using Poisson and Cox regressions.  
Results: Incidence rates (per million persons per year) for osteosarcoma were 
2.5 at age 0 – 14 years; 4.5 at age 15 – 29 years and 1.0 at age 30 – 39 years. 
Similarly, for Ewing sarcoma the incidence rates were 2.2; 2.9; 0.4 and for 
chondrosarcoma rates were 0.1; 1.2; 1.8 respectively. Incidence of 
osteosarcoma increased at an average annual rate of 2.5% (95% CI 0.4 – 4.7; P 
= 0.02), but there was no change in incidence of Ewing sarcoma or 
chondrosarcoma. There was a marginally statistically significant improvement in 
survival for Ewing sarcoma (hazard ratio (HR) per annum = 0.97; 95% CI 0.94 – 
1.00; P = 0.06), although patients aged 15 – 39 years (n = 93) had worse overall 
survival than those aged 0 – 14 (n = 73; HR = 1.46; 95% CI 0.98 – 2.17; P = 
0.06). There was no significant improvement in osteosarcoma survival (HR per 
annum = 0.98; 95% CI 0.95 – 1.01; P = 0.18).  
Conclusions: Reasons for poorer survival in Ewing sarcoma patients aged 15 – 
39 years and failure to significantly improve survival for osteosarcoma patients 
requires further investigation. 
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Background 
 
Malignant bone tumours comprise 0.7% of all cancer diagnoses in the UK [1]. For 
all ages they have an age-standardised rate of 8 per 1,000,000 persons per year 
in males and 6 per 1,000,000 persons per year in females (standardised to the 
world population [2]). These tumours are the third most frequently occurring 
malignancy diagnosed in those aged 10 – 24 years and comprise more than 
twenty diagnostic sub-groups. Osteosarcoma is the most common sub-group, 
accounting for around a third of all diagnoses [3, 4]. 
 
Primary bone cancer is rarely diagnosed in children before the age of five or 
adults over the age of sixty [3]. Incidence of osteosarcoma increases with age 
until a peak in late childhood or adolescence around the time of puberty, after 
which incidence declines. A second less pronounced peak occurs in older adults 
aged more than 65 years. Ewing sarcoma has an incidence peak in the late 
teenage years, whilst chondrosarcoma peaks in older adults (aged >65 years) [4 
– 6]. A small number of studies have explored the incidence and survival of 
childhood bone cancer [7 – 15]. However, even fewer studies have examined 
incidence and survival in those aged over 24 years. 
 
We have previously analysed incidence and survival of bone cancer in children 
(aged 0 – 14 years) from northern England and the West Midlands [15]. The aim 
of the present study was to extend the age range analysed to include cases aged 
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up to 39 years old. It is important to analyse this age-range as the incidence of 
both osteosarcoma and Ewing sarcoma peak after childhood (in those aged 
more than 15 years). We describe the incidence and survival from osteosarcoma, 
chondrosarcoma and Ewing sarcoma diagnosed in 0 – 39 year olds in northern 
England during the period 1981 – 2002 and compare patients aged 15 – 39 
years with those aged 0 – 14 years. It should be noted that the childhood cases 
aged 0 – 14 years from the region were also included in the previous analysis (82 
osteosarcoma; 73 Ewing sarcoma; 2 chondrosarcoma) [15]. The present study 
also updates previous analyses from northern England and the whole of Great 
Britain [9, 16].     
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Methods  
 
Study Subjects 
Data were included for all patients aged 0 – 39 years registered during the period 
1981 – 2002 by the Northern and Yorkshire Cancer Registry and Information 
Service (NYCRIS). This is a regional registry that records all cases of cancer and 
covers an area in the north of England with a population of approximately 6.6 
million. The registry is population-based and has a very high level of 
ascertainment due to rigorous data collection procedures [17]. 
 
NYCRIS receives notifications of all malignancies diagnosed in the region from a 
variety of sources, the main source being pathology reports that are routinely 
submitted by all health care providers (National Health Service Trusts) in the 
area. Six months after diagnosis registry staff visit the hospital of primary 
treatment to manually extract additional clinical information from the patients’ 
case notes. They check that tumour deaths correspond with the information on 
the original data source and amend when necessary. 
 
In our study, records of primary malignant bone tumours registered between 
1981 and 2002 in patients aged 0 – 39 years were extracted from NYCRIS.  All 
tumours were categorised according to The World Health Organization 
Classification of Tumours system [18]. Secondary and benign bone tumours 
were excluded from this study. Information available for each case included 
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demographic data (sex; date of birth); tumour diagnosis (date; site and 
morphology) and follow-up (current status; date of death; date of last follow-up). 
Analyses focussed on the three main diagnostic sub-groups: osteosarcoma; 
Ewing sarcoma and chondrosarcoma. 
 
Statistical Methods 
Age-specific incidence rates per million persons per year were calculated based 
on annual mid-year population estimates for the study region obtained from 
Office for National Statistics. Comparisons of age-standardised incidence rates 
(ASRs) are only meaningful if they are standardised in the same way. The world 
standard has the most widespread use and calculation of world ASRs allows 
comparisons to be made with other published UK and international (especially 
European) studies [3, 9, 11, 15]. ASRs were calculated using the age-specific 
incidence rates for five-year age groups weighted using the standard world 
population (originally proposed by Segi, but modified by Doll and colleagues and 
constructed from the pooled populations of forty six representative countries that 
had accurate population census data) [2, 19 – 21]. Poisson regression was used 
to model the effects on incidence rate for time period of diagnosis (1981 – 1988, 
1989 – 1995, 1996 – 2002); age group (0 – 14, 15 – 29, 30 – 39 years) and sex.  
Cases were followed up until 31st December 2005. Five-year survival rates were 
calculated for all cases diagnosed during the period 1981 – 2000 as follow up 
was only available for all cases until the end of 2005. Survival rates were 
calculated using Kaplan-Meier estimation [22] and differences in survival 
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between diagnostic groups (osteosarcoma, Ewing sarcoma and 
chondrosarcoma) assessed using log-rank tests. Cox Proportional Hazards 
regression analysis was used to model the probability of survival in relation to 
age, sex and year of diagnosis. Statistical significance was taken to be P < 0.05 
and marginal significance as 0.05 ≤  P < 0.1 in all analyses. All statistical 
analyses were performed using Stata version 10.  
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Results 
 
 
There were 509 patients aged less than 40 years diagnosed with a malignant 
bone tumour in the NYCRIS area during the period 1981 to 2002. The number of 
cases and age-standardised incidence rates by diagnostic group, sex and age 
group are shown in Table 1. The most common bone cancer sub-groups 
diagnosed in 0 – 39 year olds were osteosarcoma (236 cases, by sub-type: 209 
osteoblastic; 14 chondroblastic; 6 fibroblastic; 5 telangiectatic and 2 small cell) 
and Ewing sarcoma (166 cases). These comprised 46% and 33% of diagnoses 
respectively. Other sub-groups were diagnosed in smaller numbers with 73 
chondrosarcoma cases (14% of diagnoses; by sub-type: 71 central and 2 others) 
and 34 cases of other specified and unspecified bone tumours (7%). The latter 
heterogeneous group of other specified and unspecified tumours was not 
analysed. Age standardised incidence rates per million population years for each 
of the bone cancer sub-groups were 2.97 (95% CI 2.59 – 3.35) for 
osteosarcoma; 0.78 (95% CI 0.60 – 0.96) for chondrosarcoma and 2.14 (95% CI 
1.82 – 2.47) for Ewing sarcoma. 
 
Incidence varied by age group (Table 1). Poisson regression models showed that 
after adjustment for sex and time period the incidence peaked among 15 – 29 
year olds. The incidence rate ratios (IRRs) for those aged 15 – 29 years relative 
to 0 – 14 years were 2.04 (95% CI 1.55 – 2.68) for osteosarcoma; 22.33 (95% CI 
5.38 – 92.73) for chondrosarcoma and 1.44 (95% CI 1.05 – 1.97) for Ewing 
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sarcoma. The IRRs relative to the 0 – 14 age group for ages 30 – 39 were 0.45 
(95% CI 0.28 – 0.75) for osteosarcoma; 34.34 (95% CI 8.26 – 142.76) for 
chondrosarcoma and 0.21 (95% CI 0.10 – 0.44) for Ewing sarcoma.  
 
There were more male than female cases of all bone cancer combined (310 
males, 199 females; P < 0.001) and for each of the sub-groups. The IRRs for 
males relative to females were 1.49 (95% CI 1.15 – 1.94) for osteosarcoma; 1.81 
(95% CI 1.12 – 2.92) for chondrosarcoma and 1.42 (95% CI 1.04 – 1.93) for 
Ewing sarcoma.  
 
The results of the analyses of time trends in bone cancer incidence during 1981 
– 2002 are shown in Table 2. There was a statistically significant increase in the 
incidence of osteosarcoma of 2.54% per annum (95% CI 0.43 – 4.65; P = 0.02). 
There was little evidence for any temporal changes in the incidence rates for 
other diagnostic groups.  
 
Five-year survival rates by period of diagnosis by bone cancer sub-group are 
shown in Table 3. For all bone cancers combined 57% (95% CI 52 – 61) of 0 –
 39 year olds survived for at least five years. Five-year survival rates for 
diagnostic sub-groups were 58% (95% CI 51 – 64) for osteosarcoma; 71% (95% 
CI: 59 – 81) for chondrosarcoma and 43% (95% CI 35 – 51) for Ewing sarcoma. 
There was evidence of significant differences in survival rates among the 
diagnostic groups (log-rank test: P < 0.001). Significantly better survival rates 
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were found for chondrosarcoma compared with osteosarcoma (P = 0.001) and 
for osteosarcoma compared with Ewing sarcoma (P = 0.001) (Figure 1). 
  
Ewing sarcoma exhibited a higher risk of death for subjects aged 15 – 39 than 
those aged 0 – 14 (HR = 1.46 95% CI 0.98 – 2.17; P = 0.06) (Figure 2). After 
adjusting for age in the Cox model, the overall risk of death was estimated to 
decrease by 2.8% for each increasing year of diagnosis (HR per annum = 0.97 
95% CI 0.94 – 1.00; P = 0.06). There was no evidence for differences in survival 
from Ewing sarcoma between males and females (P = 0.83).  
 
For osteosarcoma there was a non-statistically significant improvement in 
survival during the study period (HR per annum = 0.98; 95% CI 0.95 – 1.01; P = 
0.18). There was no significant evidence that sex (P = 0.11) or age (P = 0.50) 
had any effect on survival.  Survival rates for chondrosarcoma remained constant 
(HR per annum = 1.00; 95% CI 0.94 – 1.07; P = 0.89) and there was no evidence 
that sex (P = 0.46) or age (P = 1.00) had any significant effect on survival. 
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Discussion 
  
This study of primary bone cancer in 0 – 39 years olds in northern England is the 
most recent analysis that has examined incidence and survival for this age 
group. Cases were limited to those aged less than forty years because this is the 
upper age-limit for entry into most clinical trials [16, 23]. Furthermore, this age 
range coincides with the peak age-incidence distribution for the majority of 
malignant primary bone tumours. It is likely that a substantial proportion of the 0 
– 39 year old patients have been treated according to trial protocols (although we 
did not have access to data on trial entry).  The basic case incidence and survival 
data were accurately recorded by the registry. However, data on stage and 
treatment were not consistently and reliably recorded. Therefore, some of the 
differences in survival may be due to differences in case mix with respect to 
stage or treatment regime. 
 
Although there is some evidence for an improvement in survival from Ewing 
sarcoma during the period 1981 – 2000, cases aged 15 – 39 years had worse 
outcome than those aged 0 – 14 years. In contrast, for osteosarcoma, there was 
no significant change in survival throughout the study period and no evidence 
that cases aged 15 – 39 years had worse outcome than childhood cases (aged 0 
– 14 years). 
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The incidence rates reported in the present study were similar to those reported 
in other countries with mainly white populations. In addition, the predominance of 
osteosarcoma and Ewing sarcoma found in this study are also typical patterns 
reported in ethnically similar populations (5% were minority ethnic population) 
[24, 25].  
 
Incidence of osteosarcoma, chondrosarcoma and Ewing sarcoma was higher 
among males than females. This is consistent with previous literature, which has 
reported that although males and females tend to show similar incidences in 
childhood [11, 15, 24], when an extended age range is included, all three 
diagnostic groups are more common in males [25]. 
 
Osteosarcoma and Ewing sarcoma both had incidence peaks in the 15 – 29 age 
group. This is consistent with previous studies, which have widely reported 
incidence of these two diagnostic groups to rise after the onset of puberty, when 
young people are undergoing a growth spurt and bones experience rapid growth 
[8, 11, 24]. 
 
This study found an increase in the incidence of osteosarcoma, but no temporal 
changes in the incidence of Ewing sarcoma and chondrosarcoma during the 
period 1981 – 2002. In both the USA and Europe, overall bone cancer incidence 
across all age groups has been reported to have remained steady over the last 
30 years [25, 26].   
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We have previously analysed the survival of children resident in northern 
England and the West Midlands during the same time period [15]. For children 
we found that whilst there was an improvement in survival from Ewing sarcoma, 
there was no improvement for osteosarcoma. The present study confirms that 
the lack of improvement in survival for osteosarcoma also applies at ages 15 – 
39 years. However, it has indicated a worse outcome for Ewing sarcoma cases in 
age group 15 – 39 years. Another recent study from the USA analysed data from 
the Surveillance, Epidemiology and End Results Program and has found that 
there has been no statistically significant improvement in survival from 
osteosarcoma (at all ages) from 1984 to 2004 [27]. 
 
The most recent national data from Great Britain reported five-year survival rates 
of 53% and 51% for cases aged 0 – 39 years during 1990 – 1994 [16]. Our data 
have shown that survival for northern England was better for osteosarcoma 
(58%) but worse for Ewing sarcoma (43%). Data for patients of all ages, from the 
United States National Cancer Database, also reported worse five-year survival 
(51.2%) for osteosarcoma and better five-year survival (50.2%) for Ewing 
sarcoma [28]. Better survival of osteosarcoma compared with the US study is 
likely to be due to the exclusion of patients aged more than 40 years from the 
present study. Another study of osteosarcoma from Finland reported five-year 
survival of 65% during 1981 – 1990 [29]. However, survival rates in northern 
England were similar to 15 – 24 year olds from a multi-centre (twenty countries) 
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European study, which found five-year survival rates of 58% for osteosarcoma 
and 42% for Ewing sarcoma [30]. 
 
A number of studies have reported worse survival from osteosarcoma in adults 
aged more than forty years [27, 28, 31, 32]. It is very well recognized that those 
aged more than 40 years have poorer prognosis than younger patients [33]. In 
our study of 0 – 39 year olds, we only found worse outcome for cases of Ewing 
sarcoma aged 15 – 39 years, but not for osteosarcoma. However, some other 
studies have specifically studied adolescent and young adult cases and have 
indicated worse outcome in this age group for both osteosarcoma and Ewing 
sarcoma compared with children [22, 34, 35]. 
 
The worse survival in cases of Ewing sarcoma aged 15 – 39 years is consistent 
with previous studies and may be due to a number of different factors including 
treatment, delays in diagnosis, metastatic disease, site and the stage of the 
tumour [36 – 39]. We were not able to investigate these factors within the scope 
of the present study. However, these issues will be addressed in future studies 
that focus on the Teenage and Young Adult (TYA) age group. A special National 
Cancer Research Institute TYA Clinical Studies Development Group has been 
formed and will oversee analyses of a new national TYA cancer dataset.  
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Conclusion 
This study has found an increase in the incidence of osteosarcoma, but no 
change in the incidence of Ewing sarcoma or chondrosarcoma. There was a lack 
of improved survival from osteosarcoma in both childhood and young adult cases 
and worse survival in Ewing sarcoma patients aged 15 – 39 years compared to 
those aged 0 – 14 years. Further research is needed to elicit the reasons for the 
failure to improve survival for osteosarcoma patients and for worse survival in 
older Ewing sarcoma patients.
 16
Competing interests 
The authors declare that they have no competing interests. 
 
Authors’ contributions 
RE, RGF, PWJ, EM and RJQM contributed to the design of the study, the writing 
of the manuscript and the analysis and interpretation of data. KB, DF, PAM and 
MSP contributed to the writing of the manuscript and the interpretation of data. 
All authors read and approved the final manuscript. 
 
Acknowledgements 
We thank the Northern and Yorkshire Cancer Registry and Information Service 
(NYCRIS) for providing data for this study. We also thank the following for 
financial support: The Bone Cancer Research Trust, Candlelighters Trust and the 
North of England Children’s Cancer Research Fund.  We are very grateful to Dr 
Quentin Campbell-Hewson for critical review of treatment data. 
 
 
 17
References  
1.   Office for National Statistics: Cancer Statistics registrations: registrations of  
 cancer diagnosed in 2005, England. Series MB1 no.36. London UK: HMSO;  
 2008. 
 
2.   Smith PG: Comparison between registries: age-standardized rates. In  
      Cancer Incidence in Five Continents. Volume VI. Edited by Parkin DM, 
      Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Lyon, France: IARC 
      Scientific Publications; 1992. 
 
3. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P 
(Eds): Cancer Incidence in Five Continents. Volume IX.  Lyon, France: IARC 
Scientific Publications No. 160; 2007. 
 
4.   Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. Cancer Treat 
Res 2010, 152:3-13. 
 
5.   Skubitz KM, D’Adamo DR: Sarcoma. Mayo Clin Proc 2007, 82:1409-1432. 
 
6.   Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr 
Course Lect 2008, 57:673-688.  
 
7. Ajiki W, Hanai A, Tsukuma H, Hiyama T, Fujimoto I: Incidence of childhood 
cancer in Osaka, Japan, 1971-1988: reclassification of registered cases 
by Birch's scheme using information on clinical diagnosis, histology 
and primary site. Jpn J Cancer Res 1994, 85:139-146.  
 
8. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL: Trends 
in cancer incidence among children in the US.  Cancer 1996, 78:532-541. 
 
9. Cotterill SJ, Parker L, Malcolm AJ, Reid M, More l, Craft AW: Incidence and 
survival for cancer in children and young adults in the North of 
England, 1968-1995: a report from the Northern Region Young Persons' 
Malignant Disease Registry. Br J Cancer 2000, 83:397-403. 
 
10. McNally RJ, Kelsey AM, Cairns DP, Taylor GM, Eden OB, Birch JM: 
Temporal increases in the incidence of childhood solid tumors seen in 
Northwest England (1954-1998) are likely to be real. Cancer 2001, 
92:1967-1976.  
 
11. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E: Bone tumours in 
European children and adolescents, 1978-1997. Report from the 
Automated Childhood Cancer Information System project. Eur J Cancer  
2006, 42:2124-2135. 
 
 18
12. Stiller CA (Ed): Childhood Cancer in Britain: Incidence, Survival, Mortality. 
Oxford, UK: Oxford University Press; 2007. 
 
13. Arndt V, Lacour B, Steliarova-Foucher E, Spix C, Znaor A, Pastore G, Stiller 
C, Brenner H: Up-to-date monitoring of childhood cancer long-term 
survival in Europe: tumours of the sympathetic nervous system, 
retinoblastoma, renal and bone tumours, and soft tissue sarcomas.  Ann 
Oncol 2007, 18:1722-1733. 
 
14. Magnanti BL, Dorak MT, Parker L, Craft AW, James PW, McNally RJ: Sex-
specific incidence and temporal trends in solid tumours in young 
people from Northern England, 1968-2005. BMC Cancer 2008, 8:89. 
 
15. Eyre R, Feltbower RG, Mubwandarikwa E, Jenkinson HC, Parkes S, Birch 
JM, Eden TO, James PW, McKinney PA, Pearce MS, McNally RJ: Incidence 
and survival of childhood bone cancer in northern England and the 
West Midlands, 1981-2002. Br J Cancer 2009, 100:188-193.   
 
16. Stiller CA, Passmore SJ, Kroll ME, Brownbill PA, Wallis JC, Craft AW: 
Patterns of care and survival for patients aged under 40 years with bone 
sarcoma in Britain, 1980-1994. Br J Cancer 2006, 94:22-29. 
 
17. Cancer Registries Peer Review Team: NHS National Cancer Peer Review     
      Programme 2004-2007 Cancer Peer Review Report: Northern & Yorkshire  
      Cancer Registry and Information Service. National Cancer Action Team;   
      2007. 
 
18. Fletcher CD, Unni KK, Mertens F (Eds):  World Health Organization  
 Classification of Tumours. Pathology and Genetics: Tumours of Soft Tissue     
 and Bone.  Lyon, France: IARC Press; 2002. 
 
19. Bray F: Age-standardization. In Cancer Incidence in Five Continents.  
      Volume VIII. Edited by Parkin DM, Whelan SL, Gao YT, Ferlay J, Teppo L,  
      Thomas DB. Lyon, France: IARC Scientific Publications; 2002 
 
20. Segi M: Cancer mortality for selected sites in 24 countries (1950-57). Sendai,  
      Japan: Tohoku University School of Public Health; 1960. 
 
21. Doll R, Payne P, Waterhouse J (Eds): Cancer Incidence in Five Continents: A  
      Technical Report. Berlin, Germany: Springer-Verlag (for UICC); 1966 
  
22. Kaplan EL, Meier P: Non-parametric estimation from incomplete 
observations. J Am Stat Assoc 1958, 53:457-481. 
 
 
 
 19
23. Voûte  PA, Souhami RL, Nooij M, Somers R, Cortés-Funes H, van der Eijken 
JW, Pringle J, Hogendoorn PC, Kirkpatrick A, Uscinska BM, van Glabbeke M, 
Machin D, Weeden S : A phase II study of cisplatin, ifosfamide and 
doxorubicin in perable primary, axial skeletal and metastatic 
osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 
1999, 10:1211-1218. 
 
24. Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester 
DP, Menck HR: The National Cancer Data Base report on patterns of 
childhood cancer in the United States. Cancer 1997, 80:2321-2332.  
 
25. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W,  
      Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR,  
      Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER  
      Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda,  
       MD, based on November 2009 SEER data submission, posted to the SEER    
       web site, 2010. 
 
26. Coleman MP, Estève J, Damiecki P, Arslan A, Renard H: Trends in cancer 
incidence and mortality. Lyon, France: IARC Scientific Publications No. 121; 
1993. 
 
27. Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival 
rates from 1973 to 2004: data from the Surveillance, Epidemiology, and 
End Results Program. Cancer 2009, 115:1531-1543. 
 
28. Damron TA, Ward WG, Stewart A: Osteosarcoma, chondrosarcoma, and 
Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat 
Res  2007, 459:40-47. 
 
29. Sampo MM, Tarkkanen M, Kivioja AH, Takinen MH, Sankila R, Böhling TO: 
Osteosarcoma in Finland from 1971 through 1990: a nationwide study of 
epidemiology and outcome. Acta Orthop 2008, 79:861-866. 
 
30. Gatta G, Capocaccia R, De Angelis R, Stiller C, Coebergh JW, EUROCARE 
Working Group: Cancer survival in European adolescents and young 
adults.  Eur J Cancer 2003, 39:2600-2610. 
 
31. Carsi B, Rock MG:  Primary osteosarcoma in adults older than 40 years. 
Clin Orthop Relat Res 2002, 397:53-61. 
 
32. Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B,  
      Windhager R, Dominkus M, Saeter G, Bauer H, Meller I, Szendroi M, Folleras  
      G, San-Julian M, van der Eijken J: Osteosarcoma over the age of forty.   
      Eur J Cancer 2003, 39:157-163. 
 
 20
33. Harting MT, Lally KP, Andrassy RJ, Vaporciyan AA, Cox CS, Hayes-Jordan 
A, Blakely ML: Age as a prognostic factor for patients with 
osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 
2010, 136:561-570. 
 
34. Stiller CA, Desandes E, Danon SE, Izarzugaza I, Ratiu A, Vassileva-
Valerianova Z, Steliarova-Foucher E: Cancer incidence and survival in 
European adolescents (1978-1997). Report from the Automated 
Childhood Cancer Information System project. Eur J Cancer 2006, 
42:2006-2018. 
 
35. Desandes E, Lacour B, Belot A, White-Koning M, Velten M, Tretarre B, 
Sauleau EA, Maarouf N, Guizard AV, Delafosse P, Danzon A, Cotte C, 
Boutreux S, Brugières L: Cancer incidence and survival among 
adolescents and young adults in France [French]. Bull Cancer 2007, 
94:331-337. 
 
36. Cotterill SJ, Ahrens S, Paulussen M,  Jürgens HF, Voûte PA,  Gadner H, 
Craft AW: Prognostic factors in Ewing's tumor of bone: analysis of 975 
patients from the European Intergroup Cooperative Ewing's Sarcoma 
Study Group.  J Clin Oncol 2000, 18:3108-3114. 
 
37. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, 
Manfrini M, Donati D, Picci P: Prognostic factors in nonmetastatic 
Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis 
of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000, 18:4-
11.  
 
38. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt 
MC, Dickman Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, 
Vietti TJ, Miser JS: Addition of ifosfamide and etoposide to standard 
chemotherapy for Ewing's sarcoma and primitive neuroectodermal 
tumor of bone. N Engl J Med 2003, 348:694-701. 
 
39. Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt 
SL, Rao BN, Santana VM, Navid F: Analysis of prognostic factors in 
Ewing sarcoma family of tumors: review of St. Jude Children's 
Research Hospital studies. Cancer 2007, 110:375-384. 
 21
Figure Legends 
 
Figure 1: Kaplan-Meier Survival by diagnosis group  
 
Figure 2: Kaplan-Meier Survival for Ewing Sarcoma by age-group (in years) 
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